Close Menu

EHR/EMR

Data aggregator InterSystems will integrate Edico Genome's DRAGEN CGIS into EHRs for easier test ordering and bidirectional data exchange.

Meditech, one of the oldest existing EHR companies, has staked out a role in supporting precision medicine with drug-gene interaction testing.

Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.

Following some major integration issues and other data challenges, Stanford is preparing to expand genomic medicine beyond rare diseases and cancer.

Amgen will use BC Platforms' tools and services to study data in multiple indications, including cardiovascular and bone diseases, hematological malignancies, and other cancers.

Organizers will not only collect genetic data on participants, but report back genetic risks via the country's national health information system.

The project, dubbed FinnGen, was announced this week and is slated to run through mid-2023.

The Office of the National Coordinator for Health IT sees long-term potential in APIs for secure transfer of clinical and genomic data, but it's not quite there yet on the genomic side.

Josus Denny

The head of the data center for the Precision Medicine Initiative's All of Us program discusses plans to manage records on 1 million people from dozens of sites.

The companies believe the database can facilitate outcomes research, improve variant interpretations, inform drug development efforts.

Pages

CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.

Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.

Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.

In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.